Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma

Lipids in Health and Disease

Dong Li⁴  Yan Wang⁵  Qing Ma³  Yingzhi Zhou¹  Huiqing Li³  Hao Li²  Yutao Diao³ 

[1] College of Economics, Shandong University, Jinan, PR China;Department of Hematology, Tumor Center of Qilu Hospital, Shandong University, Jinan, PR China;Institute of Basic Medicine of Shandong Academy of Medical Sciences, Jinan, PR China;People's Hospital, Feicheng County, Shandong Province, PR China;College of Public Health, Shandong University, Jinan, PR China

Others  :  1212993
DOI  :  10.1186/1476-511X-8-48

 received in 2009-09-28, accepted in 2009-10-29,  发布年份 2009

【 摘 要 】

Background

The aim of the study was to evaluate the association of immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein (oxLDL-lgG) and oxLDL-lgM with the progression of esophageal squamous cell carcinoma (ESSC).

Methods

Residents from Feicheng, China aged 40 to 69 years were screened for esophageal lesions in a screening program conducted during the period of January 2008 to December 2006. There were 33 controls with normal esophageal squamous epithelium cells, 37 patients with basal cell hyperplasia, 47 with esophageal squamous cell dysplasia, and 43 with ESCC. All the participants were diagnosed by biopsy and histopathological examination. Adiponectin, oxidized low-density lipoprotein (oxLDL), autoantibodies against oxLDL (oxLDL-ab), OxLDL-lgG, and OxLDL-lgM were determined by enzyme linked immunosorbent assay (ELISA). Total cholesterol, High-density lipoprotein (HDL), triglyceride, serum albumin, and blood pressure were co-estimated. Analysis of covariance for lipid levels was used to control the influence of covariates.

Results

The level of oxLDL-lgM increased gradually along with esophageal carcinoma progression. The oxLDL-lgM levels in the ESCC group were the highest after possible covariates were controlled. Binary logistic regression showed that oxLDL-lgM had a positive correlation with the development of esophageal carcinoma, while oxLDL and oxLDL-ab had a negative correlation with ESSC. No significant association between the levels of oxLDL-lgG and adiponectin and the different stages of ESSC was observed.

Conclusion

The present study shows that the decreased oxLDL and oxLDL-ab and the elevated oxLDL-lgM serum levels may relate to the development and progression of ESSC.

【 授权许可】

   
2009 Diao et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Schuit AJ, Van Dijk CEM, Dekker JM, Schouten EG, Kok FJ: Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol 1993, 137:966-976.
• [2]Wannamethee G, Shaper AG, Whincup PH, Walker M: Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ 1995, 311:409-413.
• [3]D'Agostino RB, Belanger AJ, Kannel WB, Higgins M: Role of smoking in the U-shaped relation of cholesterol to mortality in men. The Framingham Study. Am J Epidemiol 1995, 141:822-827.
• [4]Eichholzer M, Stähelin HB, Gutzwiller F, Lüdin E, Bernasconi F: Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2000, 71:569-574.
• [5]Iribarren C, Reed DM, Burchfield CM, Dwyer JH: Serum total cholesterol and mortality. JAMA 1995, 273:1926-1932.
• [6]Smith GD, Shipley MJ, Marmot MG, Rose G: Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992, 267:70-76.
• [7]Dyer AR, Stamler J, Paul O, Shekelle RB, Schoenberger JA, Berkson DM, Lepper M, Collette P, Shekelle S, Lindberg HA: Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis 1981, 34:249-260.
• [8]Baptiste MS, Nasca PC, Doyle JT, Rothenberg RR, MacCubbin PA, Mettlin C, Metzger BB, Carlton KA: Cholesterol and cancer in a population of male civil service workers. Int J Epidemiol 1992, 21:16-22.
• [9]Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, et al.: Report of the conference on low blood cholesterol: mortality associations. Circulation 1992, 86:1046-1060.
• [10]Pekkanen J, Nissinen A, Punsar S, Karvonen MJ: Short- and long-term association of serum cholesterol with mortality: the 25-year follow-up of the Finnish cohorts of the Seven Countries Study. Am J Epidemiol 1992, 135:1251-1258.
• [11]Wannamethee G, Shaper AG, Whincup PH, Walker M: Low serum total cholesterol concentrations and mortality in middle-aged British men. BMJ 1995, 311:409-413.
• [12]Sharp SJ, Pocock SJ: Time trends in serum cholesterol before cancer death. Epidemiology 1997, 8:132-136.
• [13]Song YM, Sung JH, Kim JS: Which Cholesterol Level Is Related to the Lowest Mortality in a opulation with Low Mean Cholesterol Level: A 6.4-Year Follow-up Study of 482,472 Korean Men. Am J Epidemiol 2000, 151:739-747.
• [14]Virella G, Carter RE, Saad A, Crosswell EG, Game BA: DCCT/EDIC Study Group and Maria F. Lopes-Virella. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clinical Immunology 2008, 127:394-400.
• [15]Bar D, Williams CJ, Neuwirth AK, Mantzoros CS: Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007, 86(suppl):858s-866s.
• [16]Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996, 37:45-53.
• [17]Uchida K: 4-hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003, 42:318-343.
• [18]Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649-1654.
• [19]Gounopoulos P, Merki E, Hansen LF, Choi SH, Tsimikas S: Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol 2007, 55:821-837.
• [20]Ohashi R, Mu H, Yao Q, Chen C: Atherosclerosis: immunopathogenesis and immunotherapy. Med Sci Monit 2004, 10:255-260.
• [21]Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S: Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003, 108:2107-2112.
• [22]Petridou E, Mantzoros CS, Dessypris N, Trichopoulos D, et al.: Adiponectin in relation to childhood myeloblastic leukaemia. British J Cancer 2006, 94:156-160.
• [23]Wang Y, Li H, Diao Y, Li H, Zhang Y, Yin C, Cui Y, Ma Q, Fang X, Zhou Y, Yang Y: Relationship between oxidized LDL antibodies and different stages of esophageal carcinoma. Arch Med Res 2008, 39:760-767.
• [24]Chung FL, Nath RG, Ocando J, Nishikawa A, Zhang L: Deoxyguanosine adducts of t-4-hydroxy-2-nonenal are endogenous DNA lesions in rodents and humans: detection and potential sources. Cancer Res 2000, 60:1507-1511.
• [25]ánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C, Pérez-Carreón J, Hernández-García S, Salcido-Neyoy M, Alemán-Lazarini L, Villa-Treviño S: Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett 2005, 217:25-32.
• [26]Yang CS: Research on esophageal cancer in China: a review. Cancer Res 1980, 40:2633-2644.
• [27]Qiu SL, Yang GR: Precursor lesions of esophageal cancer in high-risk populations in Henan Province, China. Cancer 1988, 62:551-557.
• [28]Yang GR, Oiu SL: Endoscopic surveys in high-risk populations for esophageal cancer in China with special reference to precursors of esophageal cancer. Endoscopy 1987, 19:91-95.
• [29]Kelesidis I, Kelesidis T, Mantzoros CS: Adiponectin and cancer: a systematic review. British Journal of Cancer 2006, 94:1221-1225.
• [30]Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M: Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 2000, 95:135-144.
• [31]Virella G, Lopes-Virella MF: Lipoprotein autoantibodies: measurement and significance. Clin Diag Lab Immunol 2003, 10:499-505.
• [32]Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S: Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscl. Thromb Vasc Biol 2000, 20:204-209.
• [33]Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF: OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006, 47:1975-1983.
• [34]Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004, 110:1406-1412.
• [35]Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P: Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 1995, 238:1-10.
• [36]Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G: Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscl Thromb Vasc Biol 2001, 21:269-274.
• [37]Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, Shah PK, Nilsson J, Nilsson J: Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007, 38:1495-1500.
• [38]Ozer Nk, Boscoboinik D, Azzi A: New roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis. Biochem Mol Biol Intern 1995, 35:117-124.
• [39]Guyton KZ, Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med Bull 1993, 49:481-483.
• [40]Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species; role in inflammatory disease and progression to cancer. Biochem J 1996, 313:17-19.
• [41]Brown NS, Bicknell R: Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327. BioMed Central Full Text
• [42]Motta M, Pistone G, Franzone AM, Romeo MA, Di Mauro S, Giugno I, Ruello P, Malaguarnera M, Malaguarnera M: Antibodies against oxLDL serum levels in patients with hepatocellular carcinoma. Panminerva Med 2003, 45:69-73.
• [43]Kelly K, Cochran BH, Stiles CD, Leder P: Cell specific regulation in normal and neoplastic cells. Adv Cancer Res 1990, 56:1-48.
• [44]Downward J, Graves JD, Warne PH: Stimulation of P21 (MD30) ras upon T-cell activation. Nature 1990, 346:719-723.
• [45]Oberhammaer F, Burch W, Parzefall W, Breit P, Erber E, Stadler M, Schulte-Hermann R: Effect of transforming growth factor β on cell death of cultured rat hepatocytes. Cancer Res 1991, 51:2478-2485.